Diflorasone
From Wikipedia, the free encyclopedia
Diflorasone
|
|
Systematic (IUPAC) name | |
[17-(2-Acetyloxyacetyl)- 6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16- octahydrocyclopenta[a]phenanthren-17-yl] acetate | |
Identifiers | |
CAS number | |
ATC code | D07 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C26H32F2O7 |
Mol. mass | 494.525 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Diflorasone is a corticosteroid that comes in the form of a cream containing diflorasone diacetate. According the drug's maker, E. Fougera & Co., it is used for its anti-inflammatory and anti-itching qualities, like other topical corticosteroids. It is often prescribed for psoriasis and atopic dermatitis, and also for Hailey Hailey Disease (Familial Benign Pemphigus). and is considered to be of greater potency compared to other topical corticosteroids.
No long-term animal studies have been done to determine whether diflorasone could have carcinogenic properties.
Women who are breastfeeding their newborns should probably not use diflorasone since corticosteroids have been known to appear in breast milk and cause negative effects in a newborn, such as inhibited growth, but little data is available regarding whether topical corticosteroids like diflorasone would be present in great enough quantities to cause harm to an infant.